Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brimonidine tartrate: a one-month dose response study

R J Derick1, A L Robin, T R Walters

  • 1Sinai Hospital, Baltimore, USA.

Ophthalmology
|January 1, 1997
PubMed
Summary

Brimonidine tartrate effectively lowers intraocular pressure (IOP) in patients with ocular hypertension or glaucoma. The 0.2% concentration demonstrated good tolerability and efficacy for long-term IOP management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping in-vivo optic nerve head strains caused by intraocular and intracranial pressures.

Proceedings of SPIE--the International Society for Optical Engineering·2018
Same author

Screening for vision-threatening diabetic retinopathy in South India: comparing portable non-mydriatic and standard fundus cameras and clinical exam.

Eye (London, England)·2017
Same author

Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence.

Health education research·2015
Same author

Neural dysfunction in ADHD with Reading Disability during a word rhyming Continuous Performance Task.

Brain and cognition·2015
Same author

Apraclonidine hydrochloride: its past, present, and future in the therapy of chronic glaucoma.

Journal of glaucoma·2009
Same author

Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: a population based study.

Current medical research and opinion·2009

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Brimonidine tartrate is a selective alpha2-agonist used to reduce intraocular pressure (IOP).
  • Previous studies show its efficacy in reducing IOP and spikes post-laser trabeculoplasty.

Purpose of the Study:

  • To evaluate the dose-response relationship of topical brimonidine tartrate for longer-term elevated IOP management.
  • To assess efficacy and safety across different concentrations.

Main Methods:

  • A 1-month, multicentered, double-masked, randomized, placebo-controlled study.
  • 194 patients with ocular hypertension/glaucoma received brimonidine (0.08%, 0.2%, 0.5%) or placebo bilaterally every 12 hours.
  • Evaluated IOP, vital signs, visual acuity, pupil size, tear secretion, and patient comfort.

Related Experiment Videos

Main Results:

  • All brimonidine concentrations significantly reduced IOP compared to baseline and placebo.
  • Maximum IOP reductions were 20.8% (0.08%), 27.2% (0.2%), and 30.1% (0.5%).
  • The 0.2% and 0.5% groups showed greater IOP reduction than the 0.08% group; effects stabilized by day 14. Common side effects included fatigue and dry mouth. Mild, asymptomatic blood pressure decrease observed in 0.2% and 0.5% groups.

Conclusions:

  • Brimonidine tartrate, particularly the 0.2% concentration, is well-tolerated and effective for long-term elevated IOP treatment.
  • Demonstrates potential as a valuable therapeutic agent in ophthalmology.